Detalles de la búsqueda
1.
Racial and ethnic characteristics and outcomes of patients diagnosed with CLL/SLL in the United States.
Acta Haematol
; 2024 May 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-38768573
2.
Efficacy and safety of first-line therapies in EGFR-mutated advanced non-small-cell lung cancer: a network meta-analysis.
Future Oncol
; 18(16): 2007-2028, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35187947
3.
Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations.
Future Oncol
; 17(22): 2867-2881, 2021 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-33866796
4.
Healthcare resource utilization in advanced non-small-cell lung cancer: post hoc analysis of the randomized phase 3 REVEL study.
Support Care Cancer
; 29(1): 117-125, 2021 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-32318871
5.
Relative efficacy of interventions in the treatment of second-line non-small cell lung cancer: a systematic review and network meta-analysis.
BMC Cancer
; 19(1): 353, 2019 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30987609
6.
Debunking Myths While Understanding Limitations.
Am J Public Health
; 110(5): e2, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32267743
7.
A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer.
J Comp Eff Res
; 12(2): e220016, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36621905
8.
Bayesian survival extrapolation for cost-effectiveness analysis: a case study of RELAY for ramucirumab in combination with erlotinib in the treatment of non-small-cell lung cancer.
J Med Econ
; 26(1): 1479-1488, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38035666
9.
Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.
Adv Ther
; 40(7): 3135-3168, 2023 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-37221352
10.
Study of patient characteristics, treatment patterns, EGFR testing patterns and outcomes in real-world patients with EGFRm+ non-small cell lung cancer.
Curr Med Res Opin
; 38(1): 91-99, 2022 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34544302
11.
Data Integration to Improve Real-world Health Outcomes Research for Non-Small Cell Lung Cancer in the United States: Descriptive and Qualitative Exploration.
JMIR Cancer
; 7(2): e23161, 2021 Apr 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33843600
12.
Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines Initiative.
Clin Pharmacol Ther
; 108(4): 817-825, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32301116
13.
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell lung cancer.
Curr Med Res Opin
; 36(10): 1667-1675, 2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32780643
14.
Association of baseline symptom burden with efficacy outcomes: Exploratory analysis from the randomized phase III REVEL study in advanced non-small-cell lung cancer.
Lung Cancer
; 131: 6-13, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-31027699
15.
Treatment patterns, duration and outcomes of pemetrexed maintenance therapy in patients with advanced NSCLC in a real-world setting.
Curr Med Res Opin
; 35(5): 817-827, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30421624
16.
Treatment Decisions for Advanced Non-Squamous Non-Small Cell Lung Cancer: Patient and Physician Perspectives on Maintenance Therapy.
Patient
; 12(2): 223-233, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30128728
17.
Treatment Patterns by EGFR Mutation Status in Non-Small Cell Lung Cancer Patients in the USA: A Retrospective Database Analysis.
Adv Ther
; 35(11): 1905-1919, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30341504
18.
Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting.
Lung Cancer
; 120: 62-69, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29748017
19.
Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non-Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial.
Clin Lung Cancer
; 19(3): 270-279.e3, 2018 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-29373274
20.
A cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.
Clinicoecon Outcomes Res
; 9: 505-518, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-28860832